ATP13A1

Across TCGA pan-cancer cohorts, ATP13A1 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of ATP13A1’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where ATP13A1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ATP13A1 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

BLCA, COAD, and KIRP are the cancer types where ATP13A1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATP13A1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	III,IV	+1.451	<.001	11	view →
COAD	Male	III,IV	+0.971	<.001	11	view →
KIRP	All	II,III,IV	+0.895	<.001	11	view →
HNSC	Male	All	+0.787	<.001	10	view →
LIHC	Female	II,III,IV	+1.600	<.001	9	view →
STAD	All	III,IV	+1.483	<.001	9	view →
LUSC	All	II,III,IV	+0.526	<.001	7	view →
UCEC	All	All	+0.846	<.001	6	view →
BRCA	All	III,IV	+0.753	<.001	6	view →
LUAD	All	III,IV	+0.744	<.001	6	view →
CHOL	Female	All	+2.210	<.001	5	view →
READ	All	All	+0.725	.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

ATP13A1–BLCA

Open the BLCA breakdown →